Humacyte, Inc. (HUMA): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$105.04M

Year ended 2025-12-31

-$97.19M

Trailing 12 months to 2026-06-30

2020-12-31 Operating Cash Flow (USD) 2025-12-31

Period ended	Operating Cash Flow	Change YoY	Source filing
2025-12-31	-$105.04M	n/m	2026-03-27, From 2025-01-01
2024-12-31	-$98.12M	n/m	2026-03-27, From 2024-01-01
2023-12-31	-$73.31M	n/m	2025-03-31, From 2023-01-01
2022-12-31	-$71.13M	n/m	2024-03-28, From 2022-01-01
2021-12-31	-$81.19M	n/m	2023-03-24, From 2021-01-01
2020-12-31	-$55.57M	n/a	2022-03-29, From 2020-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Cash Flow	Change YoY
Humacyte, Inc. (HUMA)	2025-12-31	-$105.04M	n/m
Aligos Therapeutics, Inc. (ALGS)	2025-12-31	-$82.50M	n/m
Outlook Therapeutics, Inc. (OTLK)	2025-09-30	-$51.83M	n/m
Dyadic International Inc (DYAI)	2025-12-31	-$5.70M	n/m
Scinai Immunotherapeutics Ltd. (SCNI)	2025-12-31	-$6.03M	n/m
Inhibrx Biosciences, Inc. (INBX)	2025-12-31	-$129.79M	n/m
Surrozen, Inc. (SRZN)	2025-12-31	-$30.24M	n/m
CRISPR Therapeutics AG (CRSP)	2025-12-31	-$345.01M	n/m
CG Oncology, Inc. (CGON)	2025-12-31	-$132.35M	n/m

Compare HUMA, ALGS, OTLK, DYAI side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗